R

Rezolute Bio

Develops monoclonal antibodies for rare diseases

Senior Director - Regulatory Affairs

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeRedwood City, CA, USANo salary listedIn-person

About the Job

Requirements

  • A BS or MS degree is required; an advanced degree is desirable.
  • At least 15 years of regulatory affairs experience in the biopharmaceutical industry.
  • Significant experience with biologics development, including contributing to successful BLA submissions and approvals.
  • Experience with regulatory activities for commercial launch, such as MLR and PRC.
  • Demonstrated technical knowledge of successful submissions to regulatory agencies.
  • Knowledge of Clinical, Nonclinical, and CMC regulatory issues, quality systems, and processes.
  • Knowledge of and success with regulatory designations such as orphan, Fast Track, and Breakthrough Therapy Designation, and ex-US equivalents.
  • Experience forming global strategy and executing regulatory efforts with US, EU, and other ex-US health authorities.
  • Strong experience in rare disease drug development, including endocrinology, metabolic disorders, and/or oncology.
  • Demonstrated success in health authority interactions.
  • Deep understanding of CMC requirements for biologics, including manufacturing, comparability, and lifecycle management.
  • Working knowledge of global regulatory requirements, including EMA and PMDA, is a plus.
  • Ability to operate effectively in small to mid-sized biotech environments in a hands-on capacity.
  • Experience managing regulatory CROs, consultants, and publishers.
  • Experience managing personnel and developing goals aligned with corporate objectives within the regulatory function.
  • Ability to translate strategy into action, analyze complex issues, communicate them simply, and orchestrate plans to resolve issues and mitigate risks.
  • Conflict management and negotiation skills, and ability to identify issues, raise them to key stakeholders, and develop relevant and realistic plans, programs, and recommendations.
  • Strong leadership, communication, and cross-functional collaboration skills.

Responsibilities

  • Develop and execute regulatory strategies for biologic programs in rare disease indications, including endocrinology, metabolic, and oncology, consistent with corporate and project objectives, and gain organizational consensus on those strategies.
  • Contribute to regulatory interactions with agencies, including preparing clinical-stage IND and CTA applications, marketing BLA and MAA applications, and formal meetings.
  • Pursue expedited pathways, including Orphan Drug Designation, Fast Track, Breakthrough Therapy, and RMAT where applicable.
  • Provide regulatory guidance across Clinical Development, CMC, Nonclinical, and Commercial functions.
  • Represent Regulatory in project team discussions and present issues and solutions.
  • Proactively identify issues that could affect programs, develop strategies to address them, and communicate them to project teams and company management.
  • Align regulatory strategy with clinical development plans, applying special considerations for small patient populations and innovative trial designs.
  • Identify and mitigate regulatory risks, including risks specific to biologics.
  • Monitor emerging regulatory policies, regulations, and guidelines, and analyze their applicability to company programs and activities.
  • Support business development, due diligence, and investor communications with regulatory insights.
  • Ensure compliance with applicable laws and regulations related to product development and marketing activities.

Desired Qualifications

  • Working knowledge of global regulatory requirements, including EMA and PMDA.

About the Company

Rezolute Bio

Develops monoclonal antibodies for rare diseases

Rezolute Bio develops therapies for rare diseases, led by RZ358 for congenital hyperinsulinism and RZ402 for diabetic macular edema. RZ358 is a human monoclonal antibody that binds insulin to reduce its activity, aiming to lessen hypoglycemia, while RZ402 is an oral plasma kallikrein inhibitor for DME. The company differentiates itself by targeting rare, unmet-need conditions and pursuing late-stage candidates in both antibody and small-molecule formats. Its goal is to bring approved therapies to patients by advancing its programs through development to commercialization.

Company size
51-200
Company stage
IPO
Headquarters
Louisville, KY
Founded
2010

Recently Posted Jobs

Explore more opportunities at Rezolute Bio

See more jobs